Multicenter trial of L-Deprenylin Parkinson disease

S. Ruggieri, A. Denaro, G. Meco, A. Carta, F. Stocchi, A. Agnoli

Research output: Contribution to journalArticlepeer-review


A multicenter trial was conducted at 9 Neurology Departements to evaluate the action of L-Deprenyl, a specific monoamine oxidase-B inhibitor, combined with L-Dopa in the treatment of Parkinson disease. In all, 76 patients were treated, 33 women and 43 men, on stable treatment with L-Dopa+aromatic decarboxylase inhibitors (DI) for at least 6 months. After a 50% reduction of the L-Dopa dose, all received L-Deprenyl 5 mg twice daily for 35 day. The combined treatment resulted in a definite improvement in rigidity, bradykinesia and, most of all, tremor. Further, at the end of treatment fewer patients had depressive symptoms and the total daily number of hours of wellbeing and normal movement increased. 12 patients presented modest side effects, in no case serious enough to warrant suspension of treatment. The trial shows that with the L-Deprenyl+L-Dopa combination the dose of L-Dopa needed to control the disease can be drastically reduced.

Original languageEnglish
Pages (from-to)133-137
Number of pages5
JournalItalian Journal of Neurological Sciences
Issue number1
Publication statusPublished - Feb 1986


  • L-Deprenyl
  • Parkinson disease

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Multicenter trial of L-Deprenylin Parkinson disease'. Together they form a unique fingerprint.

Cite this